申请人:Kyowa Hakko Kogyo Co., Ltd.
公开号:US04147799A1
公开(公告)日:1979-04-03
Ethanolamine derivatives and their acid addition salts are prepared (1) by reacting a 1-(3,4-methylenedioxyphenyl)-2-aminoethanol compound or an .alpha.-amino-(3,4-methylenedioxy)acetophenone compound with an alkanal or an alkanone under reduction conditions, (2) by hydrogenating and/or hydrogenolyzing a 1-(3,4-methylenedioxyphenyl)-2-(N-substituted amino)-ethanol compound or an .alpha.-(N-substituted amino)-(3,4-methylenedioxy)acetophenone compound, and (3) by reacting a (3,4-methylenedioxyphenyl)-ethylene oxide compound or a 1-(3,4-methylenedioxyphenyl)-2-substituted ethanol compound with an amine. The ethanolamine derivatives and their salts show .beta.-adrenergic receptor blocking activity, and are expected to be useful in the treatment of heart disease, hypertension, myocardites and pheochromocytoma.
乙醇胺衍生物及其酸盐可以通过以下方法制备:(1)通过在还原条件下将1-(3,4-二甲氧基苯基)-2-氨基乙醇化合物或α-氨基-(3,4-二甲氧基)乙酮化合物与烷醛或烷酮反应,(2)通过氢化和/或氢解1-(3,4-二甲氧基苯基)-2-(N-取代氨基)-乙醇化合物或α-(N-取代氨基)-(3,4-二甲氧基)乙酮化合物,(3)通过将(3,4-二甲氧基苯基)-乙烯氧化物或1-(3,4-二甲氧基苯基)-2-取代乙醇化合物与胺反应。乙醇胺衍生物及其盐具有β-肾上腺素能受体阻滞活性,预计可用于治疗心脏病、高血压、心肌炎和嗜铬细胞瘤。